Agilent Technologies (NYSE:A - Get Free Report) had its target price cut by analysts at Wells Fargo & Company from $165.00 to $160.00 in a report released on Thursday,Benzinga reports. The brokerage currently has an "overweight" rating on the medical research company's stock. Wells Fargo & Company's target price points to a potential upside of 18.71% from the company's previous close.
Several other research firms have also recently commented on A. UBS Group decreased their price target on shares of Agilent Technologies from $180.00 to $165.00 and set a "buy" rating on the stock in a research note on Thursday, February 26th. TD Cowen reduced their price objective on Agilent Technologies from $170.00 to $157.00 and set a "buy" rating on the stock in a report on Thursday, February 26th. Barclays decreased their price objective on Agilent Technologies from $150.00 to $140.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 14th. Bank of America raised Agilent Technologies from a "neutral" rating to a "buy" rating and lowered their target price for the company from $150.00 to $145.00 in a research note on Thursday. Finally, Wall Street Zen downgraded Agilent Technologies from a "buy" rating to a "hold" rating in a research report on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $160.73.
Read Our Latest Stock Analysis on A
Agilent Technologies Price Performance
A traded up $18.95 during trading on Thursday, hitting $134.79. The company's stock had a trading volume of 1,630,510 shares, compared to its average volume of 2,183,910. The firm's 50 day moving average price is $114.99 and its two-hundred day moving average price is $128.79. The company has a quick ratio of 1.59, a current ratio of 2.07 and a debt-to-equity ratio of 0.44. The stock has a market capitalization of $38.09 billion, a price-to-earnings ratio of 29.65, a price-to-earnings-growth ratio of 2.42 and a beta of 1.22. Agilent Technologies has a 12 month low of $108.35 and a 12 month high of $160.27.
Agilent Technologies (NYSE:A - Get Free Report) last issued its quarterly earnings data on Wednesday, May 27th. The medical research company reported $1.49 EPS for the quarter, topping analysts' consensus estimates of $1.41 by $0.08. The firm had revenue of $1.84 billion for the quarter, compared to analyst estimates of $1.80 billion. Agilent Technologies had a net margin of 18.26% and a return on equity of 24.49%. The company's revenue was up 10.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.31 EPS. Agilent Technologies has set its FY 2026 guidance at 6.000-6.100 EPS and its Q3 2026 guidance at 1.480-1.500 EPS. Sell-side analysts forecast that Agilent Technologies will post 5.95 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Agilent Technologies
A number of hedge funds have recently modified their holdings of the business. Ritter Alpha LP acquired a new stake in shares of Agilent Technologies during the first quarter worth about $203,000. Summitry LLC grew its position in shares of Agilent Technologies by 8.1% in the 1st quarter. Summitry LLC now owns 673,954 shares of the medical research company's stock valued at $76,817,000 after purchasing an additional 50,441 shares during the period. Segall Bryant & Hamill LLC bought a new stake in Agilent Technologies during the 1st quarter worth approximately $9,041,000. Essential Partners LLC increased its stake in Agilent Technologies by 35.1% during the 1st quarter. Essential Partners LLC now owns 2,658 shares of the medical research company's stock worth $303,000 after purchasing an additional 690 shares in the last quarter. Finally, Groupe la Francaise raised its holdings in Agilent Technologies by 15.4% during the 1st quarter. Groupe la Francaise now owns 39,069 shares of the medical research company's stock worth $4,453,000 after buying an additional 5,217 shares during the period.
Key Agilent Technologies News
Here are the key news stories impacting Agilent Technologies this week:
- Positive Sentiment: Agilent beat Wall Street’s Q2 expectations, reporting adjusted EPS of $1.49 versus estimates around $1.41 and revenue of $1.83 billion, above forecasts, with revenue up 10% year over year. Agilent Reports Second-Quarter Fiscal Year 2026 Financial Results
- Positive Sentiment: The company raised its full-year 2026 profit outlook and also issued Q3 guidance that points to continued growth, reinforcing confidence in demand for its lab tools and diagnostic products. Agilent raises 2026 profit forecast on strong demand for lab tools
- Positive Sentiment: Bank of America upgraded Agilent from neutral to buy, which typically helps sentiment because it signals improved confidence in the stock’s upside. Benzinga report on Bank of America upgrade
- Positive Sentiment: RBC also initiated coverage with an outperform rating and a $153 price target, adding another bullish analyst call after earnings. Benzinga report on RBC coverage
- Neutral Sentiment: Agilent also highlighted new product launches and digital-lab tools, including OpenLab Sync and new GC systems, which support the longer-term growth story but are less likely to move the stock immediately. Agilent Introduces OpenLab Sync
About Agilent Technologies
(
Get Free Report)
Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company's product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.
Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Agilent Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agilent Technologies wasn't on the list.
While Agilent Technologies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
